{"id":"https://openalex.org/W2529487175","doi":"https://doi.org/10.1182/blood.v124.21.4757.4757","title":"Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?","display_name":"Is There a Preferred Infusional Regimen for Patients with Relapsed/Refractory Multiple Myeloma?","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2529487175","doi":"https://doi.org/10.1182/blood.v124.21.4757.4757","mag":"2529487175"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.4757.4757","doi":"https://doi.org/10.1182/blood.v124.21.4757.4757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4757.4757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013794060","display_name":"Patrick T. Griffin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick T. Griffin","raw_affiliation_strings":["H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066588816","display_name":"Viet Q. Ho","orcid":"https://orcid.org/0000-0002-8794-3663","observed_orcids":["https://orcid.org/0000-0002-8794-3663"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Viet Q. Ho","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052124202","display_name":"William J. Fulp","orcid":"https://orcid.org/0000-0001-6888-0794","observed_orcids":["https://orcid.org/0000-0001-6888-0794"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Fulp","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062691289","display_name":"Taiga Nishihori","orcid":"https://orcid.org/0000-0002-2621-7924","observed_orcids":["https://orcid.org/0000-0002-2621-7924"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taiga Nishihori","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053572690","display_name":"Kenneth H. Shain","orcid":"https://orcid.org/0000-0003-4178-8888","observed_orcids":["https://orcid.org/0000-0003-4178-8888"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth H. Shain","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087799564","display_name":"Melissa Alsina","orcid":"https://orcid.org/0000-0003-4946-823X","observed_orcids":["https://orcid.org/0000-0003-4946-823X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Alsina","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077110117","display_name":"Rachid Baz","orcid":"https://orcid.org/0000-0003-4538-4733","observed_orcids":["https://orcid.org/0000-0003-4538-4733"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachid Baz","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.30586961,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"124","issue":"21","first_page":"4757","last_page":"4757"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.9589999914169312},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8240000009536743},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/transplant-eligibility","display_name":"transplant eligibility","score":0.8709999918937683},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.8360000252723694},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4620000123977661},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.796999990940094},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7549999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8436614274978638},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.649779200553894},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6185632944107056},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.5968836545944214},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.570618748664856},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5550084710121155},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.5410640835762024},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5325549840927124},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.5285571813583374},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.5282860398292542},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.521284818649292},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5031034350395203},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.46064522862434387},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.43313294649124146},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.42399805784225464},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3892055153846741}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.4757.4757","doi":"https://doi.org/10.1182/blood.v124.21.4757.4757","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4757.4757","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1530475443","https://openalex.org/W4417016289","https://openalex.org/W3110350281","https://openalex.org/W2980528157","https://openalex.org/W4389234829","https://openalex.org/W4389247243","https://openalex.org/W4309119155","https://openalex.org/W2159558238","https://openalex.org/W2254978625","https://openalex.org/W2889127703"],"abstract_inverted_index":{"Abstract":[0,446],"Introduction:":[1],"Despite":[2],"the":[3,45,60,71,76,85,102,117,128,145,148,164,170,180,197,230,260,273,282,289,299,309,319,323,349,383,390,430,442],"impact":[4],"of":[5,47,75,87,95,101,147,166,175,191,196,246,288,303,348,575],"novel":[6,88],"agents,":[7],"many":[8],"patients":[9,193,341,404],"with":[10,92,367,418],"multiple":[11],"myeloma":[12],"(MM)":[13],"still":[14],"require":[15],"intensive":[16,392],"infusional":[17,62,414],"chemotherapy":[18,104,415],"regimens,":[19],"such":[20],"as":[21,276,278],"dexamethasone,":[22,28],"cyclophosphamide,":[23,37],"etoposide,":[24],"cisplatin":[25],"(DCEP),":[26],"bortezomib,":[27],"thalidomide,":[29],"cisplatin,":[30],"doxorubicin,":[31],"cyclophosphamide":[32],"and":[33,40,73,112,154,216,240,358,421],"etoposide":[34],"(VDT-PACE),":[35],"or":[36,108,257,401,513,520],"vincristine,":[38],"adriamycin,":[39],"dexamethasone":[41],"(CVAD),":[42],"especially":[43],"in":[44,84,221,233,254,272,281,380,405,426,441],"setting":[46,428],"proliferative":[48],"relapsed/refractory":[49,96,201],"disease.":[50],"To":[51],"our":[52],"knowledge,":[53],"there":[54,374],"are":[55,219],"no":[56,250,376],"published":[57],"data":[58],"comparing":[59,70],"different":[61],"regimens.":[63,262,387],"Here,":[64],"we":[65],"present":[66],"a":[67,93,267,407,435],"retrospective":[68,372],"analysis":[69,245,287,347],"efficacy":[72],"safety":[74],"three":[77,103,384],"most":[78],"commonly":[79],"used":[80,135],"MM":[81,97,202,385],"salvage":[82,167,296,386],"regimens":[83,105,199],"era":[86],"agents.":[89],"Methods:":[90],"Patients":[91],"diagnosis":[94],"who":[98],"received":[99],"one":[100,195],"(DCEP,":[106],"VDT-PACE,":[107,394],"CVAD)":[109],"between":[110,229,259,382],"01/2005":[111],"12/2013":[113],"were":[114,125,134,161,177,203,364,375],"identified":[115,204],"through":[116],"Moffitt":[118],"Total":[119],"Cancer":[120],"Care":[121],"Database.":[122],"Clinical":[123],"variables":[124],"abstracted":[126],"from":[127,163],"patient":[129,212],"records.":[130],"The":[131],"IMWG":[132],"criteria":[133],"to":[136,235,265,295,409,528,577],"assess":[137],"response.":[138],"Transplant":[139],"eligibility":[140,293],"was":[141,227,298,312,326,411,416,434],"determined":[142],"based":[143],"on":[144],"assessment":[146],"treating":[149],"physician.":[150],"Progression-free":[151],"survival":[152,156,176],"(PFS)":[153],"overall":[155],"(OS)":[157],"for":[158,200,318,339,556],"each":[159],"group":[160],"estimated":[162],"initiation":[165],"therapy":[168,225],"using":[169,179],"Kaplan-Meier":[171],"method.":[172],"Multivariate":[173],"predictors":[174],"assessed":[178],"Cox":[181],"proportional":[182],"hazards":[183],"model":[184],"by":[185],"backward":[186],"elimination.":[187],"Results:":[188],"A":[189],"total":[190],"107":[192],"receiving":[194],"3":[198,231,261],"(DCEP":[205],"52,":[206],"VDT-PACE":[207,274,454],"22,":[208],"CVAD":[209,283,456],"33).":[210],"Relevant":[211],"characteristics,":[213],"treatment":[214,247,297,310],"outcomes,":[215,420],"adverse":[217,439],"events":[218,440],"described":[220],"Table":[222,448],"1.":[223],"Prior":[224],"history":[226],"similar":[228],"groups":[232],"regard":[234],"lenalidomide":[236],"(77.6%),":[237],"bortezomib":[238],"(88.8%),":[239],"autologous":[241],"transplant":[242,292,343,350,410],"(53.3%).":[243],"An":[244],"outcomes":[248,381],"revealed":[249],"statistically":[251,377],"significant":[252,301,314,378,431],"differences":[253,379],"response,":[255],"PFS,":[256,535],"OS":[258,304,325],"There":[263,433],"appeared":[264],"be":[266,424],"trend":[268,436],"towards":[269,437],"more":[270,391],"FN":[271],"group,":[275],"well":[277],"prolonged":[279],"hospitalization":[280],"group.":[284],"On":[285,345],"multivariate":[286,346],"entire":[290],"cohort,":[291],"prior":[294],"only":[300,327],"predictor":[302],"(HR":[305,355,361],"0.22,":[306],"p<0.001),":[307],"whereas":[308],"regimen":[311],"not":[313,396,412,423],"(p=0.411).":[315],"In":[316,370],"fact,":[317],"non-transplant":[320],"eligible":[321,351],"population,":[322,352],"median":[324,461,467],"3.09":[328],"months":[329,335],"(95%":[330,336,537,544],"CI,":[331],"2.17-4.02),":[332],"versus":[333],"16.70":[334],"CI":[337],"11.45-21.97)":[338],"those":[340],"deemed":[342],"eligible.":[344],"performance":[353],"status":[354],"2.10,":[356],"p=0.012)":[357],"extramedullary":[359],"disease":[360,399],"3.71,":[362],"p=0.002)":[363],"significantly":[365],"correlated":[366],"OS.":[368],"Conclusions:":[369],"this":[371],"analysis,":[373],"Of":[388],"note,":[389],"regimen,":[393],"did":[395],"demonstrate":[397],"superior":[398],"response":[400],"survival.":[402],"For":[403],"whom":[406],"bridge":[408],"planned,":[413],"associated":[417],"poor":[419],"should":[422],"considered":[425],"that":[427],"given":[429],"toxicities.":[432],"fewer":[438],"DCEP":[443,452],"treated":[444],"patients.":[445],"4757.":[447],"1.Characteristics,":[449],"N":[450,473,481,488,502,508,515,522,530,550],"(%)":[451],"n=52":[453],"n=22":[455],"n=33":[457],"p-value":[458],"Age":[459],"(yrs),":[460],"(range)57.6":[462],"(43-73)54.5":[463],"(29-68)56.9":[464],"(41-73)0.054Creatinine":[465],"(mg/dL),":[466],"(range)0.90":[468],"(0.6-2.8)1.25":[469],"(0.6-6.6)2.20":[470],"(0.6-12.9)<0.001Extramedullary":[471],"Disease,":[472],"(%)15":[474],"(28.8)7":[475],"(31.8)3":[476],"(9.1)0.056Circulating":[477],"Plasma":[478],"Cells":[479],">5%,":[480],"(%)4":[482],"(7.7)4":[483],"(18.2)7":[484],"(21.2)0.169High":[485],"Risk":[486],"Cytogenetics,":[487],"(%)18":[489],"(34.6)6":[490],"(27.3)8":[491],"(24.2)0.803+1q219":[492],"(17.3)1":[493],"(4.5)2":[494],"(6.1)t(4;14)5":[495],"(9.6)02":[496],"(6.1)-17p11":[497],"(21.2)6":[498],"(27.3)4":[499],"(12.1)Prior":[500],"Regimens,":[501],"(%)3":[503],"(1-9)3":[504],"(1-13)3":[505],"(1-7)0.514Transplant":[506],"Eligible,":[507],"(%)32":[509],"(61.5)14":[510],"(63.7)17":[511],"(51.5)0.578OutcomesVGPR":[512],"better,":[514,521],"(%)9":[516],"(17.3)7":[517],"(31.8)4":[518],"(12.1)0.284PR":[519],"(%)27":[523],"(51.9)16":[524],"(72.7)16":[525],"(48.5)0.386Successful":[526],"Bridge":[527],"Transplant,":[529],"(%)20/32":[531],"(62.5)8/14":[532],"(57.1)11/17":[533],"(64.7)0.907Median":[534],"mo.":[536,543],"CI)3.78":[538],"(1.96-5.60)4.54":[539],"(1.67-7.41)5.79":[540],"(2.10-9.48)0.801Median":[541],"OS,":[542],"CI)8.26":[545],"(5.52-10.99)8.52":[546],"(3.16-13.87)8.22":[547],"(0.00-18.46)0.835Adverse":[548],"Events,":[549],"(%)Prolonged":[551],"Hospitalization4":[552],"(7.7)1":[553],"(4.5)7":[554],"(21.2)0.084Re-Hospitalization":[555],"Adverse":[557],"Event15":[558],"(29.4)8":[559],"(36.4)13":[560],"(40.6)0.563Febrile":[561],"Neutropenia15":[562],"(29.4)11":[563],"(50.0)13":[564],"(39.4)0.230Treatment":[565],"Related":[566],"Mortality3":[567],"(5.8)1":[568],"(4.5)3":[569],"(9.1)0.762":[570],"Disclosures":[571],"No":[572],"relevant":[573],"conflicts":[574],"interest":[576],"declare.":[578]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-10-14T00:00:00"}